NASDAQ:LUNG

Pulmonx Competitors

$45.01
+1.94 (+4.50 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.49
Now: $45.01
$46.18
50-Day Range
$43.07
MA: $52.51
$61.64
52-Week Range
$37.64
Now: $45.01
$69.48
Volume446,585 shs
Average Volume258,716 shs
Market Capitalization$1.61 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pulmonx (NASDAQ:LUNG) Vs. INSP, HAE, IART, NARI, TNDM, and NVRO

Should you be buying LUNG stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Pulmonx, including Inspire Medical Systems (INSP), Haemonetics (HAE), Integra LifeSciences (IART), Inari Medical (NARI), Tandem Diabetes Care (TNDM), and Nevro (NVRO).

Pulmonx (NASDAQ:LUNG) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Inspire Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Inspire Medical Systems03802.73

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Inspire Medical Systems has a consensus price target of $168.5455, suggesting a potential downside of 23.81%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Inspire Medical Systems.

Valuation & Earnings

This table compares Pulmonx and Inspire Medical Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Inspire Medical Systems$82.05 million73.25$-33,240,000.00($1.40)-158.01

Pulmonx has higher earnings, but lower revenue than Inspire Medical Systems.

Insider & Institutional Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. 6.6% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Inspire Medical Systems-61.07%-32.23%-26.42%

Summary

Inspire Medical Systems beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Haemonetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Haemonetics00403.00

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.17%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Haemonetics.

Valuation & Earnings

This table compares Pulmonx and Haemonetics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Haemonetics$988.48 million6.04$76.53 million$3.3135.52

Haemonetics has higher revenue and earnings than Pulmonx.

Insider & Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Haemonetics11.76%22.85%10.40%

Summary

Haemonetics beats Pulmonx on 8 of the 11 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Integra LifeSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Integra LifeSciences14402.33

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Integra LifeSciences has a consensus price target of $67.8889, suggesting a potential downside of 2.90%. Given Pulmonx's stronger consensus rating and higher probable upside, research analysts clearly believe Pulmonx is more favorable than Integra LifeSciences.

Valuation & Earnings

This table compares Pulmonx and Integra LifeSciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Integra LifeSciences$1.52 billion3.89$50.20 million$2.7425.52

Integra LifeSciences has higher revenue and earnings than Pulmonx.

Insider & Institutional Ownership

85.7% of Integra LifeSciences shares are owned by institutional investors. 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Integra LifeSciences4.10%14.26%5.77%

Summary

Integra LifeSciences beats Pulmonx on 7 of the 11 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Inari Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Inari Medical01502.83

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Inari Medical has a consensus price target of $116.1667, suggesting a potential upside of 1.95%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than Inari Medical.

Valuation & Earnings

This table compares Pulmonx and Inari Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Inari MedicalN/AN/AN/AN/AN/A

Inari Medical has lower revenue, but higher earnings than Pulmonx.

Insider & Institutional Ownership

17.8% of Inari Medical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Inari Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Inari MedicalN/AN/AN/A

Pulmonx (NASDAQ:LUNG) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Pulmonx and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Tandem Diabetes Care-11.10%-10.98%-5.59%

Valuation & Earnings

This table compares Pulmonx and Tandem Diabetes Care's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Tandem Diabetes Care$362.30 million15.18$-24,750,000.00($0.22)-399.95

Pulmonx has higher earnings, but lower revenue than Tandem Diabetes Care.

Insider & Institutional Ownership

88.6% of Tandem Diabetes Care shares are owned by institutional investors. 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Pulmonx and Tandem Diabetes Care, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Tandem Diabetes Care04902.69

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 28.86%. Tandem Diabetes Care has a consensus price target of $115.9231, suggesting a potential upside of 31.75%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than Pulmonx.

Summary

Tandem Diabetes Care beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Nevro (NYSE:NVRO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Pulmonx and Nevro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Nevro-24.46%-30.25%-14.57%

Earnings & Valuation

This table compares Pulmonx and Nevro's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million49.28$-20,700,000.00N/AN/A
Nevro$390.26 million12.96$-103,690,000.00($3.37)-43.36

Pulmonx has higher earnings, but lower revenue than Nevro.

Analyst Ratings

This is a summary of current recommendations and price targets for Pulmonx and Nevro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Nevro031102.79

Pulmonx currently has a consensus target price of $58.00, suggesting a potential upside of 28.86%. Nevro has a consensus target price of $181.3846, suggesting a potential upside of 24.13%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Nevro.

Summary

Pulmonx beats Nevro on 6 of the 9 factors compared between the two stocks.


Pulmonx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$221.22+1.7%$6.01 billion$82.05 million-95.35
Haemonetics logo
HAE
Haemonetics
1.6$117.56+0.8%$5.97 billion$988.48 million56.79
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.92+0.7%$5.90 billion$1.52 billion104.36Insider Selling
Inari Medical logo
NARI
Inari Medical
1.1$113.94+0.0%$5.55 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99+0.3%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$146.13+1.2%$5.06 billion$390.26 million-53.72News Coverage
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$141.40+7.0%$4.93 billion$42.93 million-70.00
ICU Medical logo
ICUI
ICU Medical
1.5$206.00+0.2%$4.37 billion$1.27 billion54.50Insider Selling
Glaukos logo
GKOS
Glaukos
0.9$82.94+0.5%$3.80 billion$236.98 million-50.27Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
1.3$84.97+0.9%$3.59 billion$1.02 billion101.16
NuVasive logo
NUVA
NuVasive
1.1$68.49+0.1%$3.52 billion$1.17 billion-311.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$60.95+0.4%$3.39 billion$994.85 million-115.00
AtriCure logo
ATRC
AtriCure
1.5$65.96+0.2%$3.01 billion$230.81 million-57.36Analyst Report
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$85.71+6.2%$2.50 billion$214.55 million-44.87Analyst Report
Unusual Options Activity
Gap Up
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$58.50+1.3%$2.43 billion$13.82 million-29.85
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.73+5.6%$1.82 billion$4.11 million-6.42
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.4%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.95+0.2%$1.75 billion$334.64 million94.75Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.00+0.9%$1.72 billion$63.35 million-40.98
Alphatec logo
ATEC
Alphatec
0.8$17.13+0.2%$1.63 billion$113.43 million-15.57Insider Selling
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.51+0.6%$1.47 billion$236.54 million-55.32
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.40+0.1%$1.38 billion$299.26 million-13.19
Atrion logo
ATRI
Atrion
1.1$645.10+0.0%$1.18 billion$155.07 million36.34
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$55.26+2.6%$1.08 billion$189.49 million-122.80
SI-BONE logo
SIBN
SI-BONE
1.2$32.97+2.1%$1.08 billion$67.30 million-20.61Increase in Short Interest
Cerus logo
CERS
Cerus
1.7$6.26+3.0%$1.05 billion$74.65 million-16.05News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.99+0.2%$1.03 billion$117.23 million53.75
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.06+0.6%$964.42 million$72.55 million-34.07
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.03+2.9%$916.43 million$264.16 million-5.38Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.78+1.3%$891.15 million$276.22 million-59.95
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.46+3.2%$847.99 million$459.95 million36.22
Surmodics logo
SRDX
Surmodics
1.3$57.49+0.8%$790.83 million$94.86 million718.63
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.32+2.6%$742.48 million$154.60 million-44.87
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.04+0.7%$679.37 million$123.86 million67.34
Intersect ENT logo
XENT
Intersect ENT
1.4$19.75+1.5%$652.07 million$109.14 million-10.34
Vapotherm logo
VAPO
Vapotherm
1.5$23.08+0.8%$595.63 million$48.10 million-10.99
SeaSpine logo
SPNE
SeaSpine
1.3$21.12+1.3%$589.95 million$159.08 million-12.65
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.42+0.0%$579.22 million$114.51 million-86.00
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.34+1.4%$556.70 millionN/A-9.40
Accuray logo
ARAY
Accuray
2.3$5.22+0.8%$484.93 million$382.93 million37.29News Coverage
iCAD logo
ICAD
iCAD
1.7$18.10+1.2%$451.02 million$31.34 million-19.05
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.76+0.8%$449.02 million$14.26 million-10.03Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.11+6.8%$415.73 million$11.22 million-45.70News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.44+2.3%$414.73 million$4.17 million-17.47News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.25+2.8%$400.19 million$24.95 million-28.03
PAVmed logo
PAVM
PAVmed
1.4$4.76+21.4%$392.51 millionN/A-6.26
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.28+1.3%$370.59 million$198.38 million24.64
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.17+5.3%$370.01 million$2.84 million0.00
Soliton logo
SOLY
Soliton
1.1$16.63+2.0%$352.56 millionN/A-22.17
Neuronetics logo
STIM
Neuronetics
1.5$12.71+1.2%$322.94 million$62.66 million-7.57
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.